shareholdersunite.com

The regulatory approval process for new drugs is Byzantine, lengthy, and unpredictable. Single stocks are, for outsiders at least (even insiders can be surprised), almost pure bets. But one can still profit from the usual fact that the winnings are often much larger than the possible losses…

[Read more →]